Former Pharma execs launch BioEndpoint Consulting

Three former pharmaceutical industry veterans have launched a new consulting firm to help small and mid-sized drug and medical device companies with the development and commercialization of new products.

The new company, called BioEndpoint Consulting, will work with the industry to help companies focus on getting their products to market.

Co-managing partner Jeff Sherman said smaller medical companies face a number of roadblocks as they move to get their products out of the research and development stage.

"The pharmaceutical industry as a whole has a special set of challenges ranging from losses in patent protection, to toughening regulatory hurdles, and stricter cost controls,” Sherman added. "These pressures, combined with the intensifying struggle to differentiate products from market competitors, have put a vice grip on commercialization teams with smaller budgets and larger workloads."

Sherman and his other partners, Matthew Ruple and Jim Garrison, each have between 15 and 25 years experience in the medical industry. Services will include marketplace evaluation, care and pricing strategy, sales projects, acquisition negotiation and commercial launch planning.